Grace Therapeutics, Inc.

Princeton, NJ · Biotech · Public

Therapeutic treatment for aneurysmal subarachnoid hemorrhage targeting prevention of vasospasm

Claim this profile

Follows are private to you and power your alerts

Updated · gracetx.com

Sector
Biotech
Headquarters
Princeton, NJ
Latest Form D
$15M, Feb 2025
Total capital
$23M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$23M
4 Form D · last Feb 2025
20 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
1
3 pending · first 2024
Rank in peer group#481 of 1449

Capital timeline

20112013201520172019202120232025FEDERAL ↑EQUITY ↓Cumulative $23M1st Form D$170K2nd Form D$373K3rd Form D$7.5M
2011201520192023FEDERAL ↑EQUITY ↓Cumulative $23M2nd Form D$373K3rd Form D$7.5M

Latest events

  • Private capital raisedForm D · SEC · 4th filing$15M
  • Private capital raisedForm D · SEC · 3rd filing$7.5M
  • Private capital raisedForm D · SEC · 2nd filing$373K
  • Private capital raisedForm D · SEC · 1st filing$170K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 1449 peers

Line = median

Biotech · Molecule

  • Granted patents#481 · top 33%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants
  • S. George KottayilResearcherDirectorLinked by 1 patent
  • A. Brian DavisDirectorNamed in SEC Form D filings
  • Amresh KumarExecutive OfficerNamed in SEC Form D filings
  • Carrie D'AndreaExecutive OfficerNamed in SEC Form D filings
  • Dr. R. Loch MacdonaldExecutive OfficerNamed in SEC Form D filings
  • Edward NeugeborenDirectorNamed in SEC Form D filings
Show all 9 people
  • Prashant KohliDirector, Executive OfficerNamed in SEC Form D filings
  • Robert J. DelAversanoExecutive OfficerNamed in SEC Form D filings
  • Vimal KavuruDirectorNamed in SEC Form D filings

What it has protected

USPTO · 1 granted of 4
  • GrantedStable Nimodipine Parenteral FormulationUSPTOUS 12,059,415
  • PendingTopical Film-forming SprayUSPTOApplication 17554533
  • PendingTopical Film-forming SprayUSPTOApplication 17554564
Show all 4 patent records
  • Stable Nimodipine Parenteral FormulationAug 13, 2024 · US 12,059,415Granted
  • Topical Film-forming SprayMay 5, 2022 · Application 17554533Pending
  • Topical Film-forming SprayMay 5, 2022 · Application 17554564Pending
  • Nimodipine Parenteral AdministrationApplication 63342204Pending

Press

1 article · matched on company name

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .